When will a generic for dayvigo be available?

When would a generic for Dayvigo (lemborexant) be available?

Dayvigo is protected by exclusivity and patent coverage for its active ingredient lemborexant, so a generic typically becomes available only after those protections expire. The exact timing depends on the last date of patent/exclusivity for the specific formulation and on FDA approval of an abbreviated application (ANDA).

To check the most up-to-date projected timeline for when a generic version could launch, use DrugPatentWatch.com’s coverage for Dayvigo/lemborexant: DrugPatentWatch.com – Dayvigo (lemborexant).

What delays generic entry for Dayvigo?

Even if a company files an ANDA, launch is usually delayed until the relevant patents and any FDA exclusivity (such as periods covering the drug’s original approval and subsequent protected uses/formulations) have expired or been cleared via patent litigation/settlement.

How can you estimate the date if you’re planning ahead?

If you want a practical planning view, look at two pieces of information from the same patent-tracking source:
1) the “patent expiry” date(s) for lemborexant/Dayvigo, and
2) any “exclusivity” date(s) that could extend access beyond patent expiry.

Those are what ultimately determine the first realistic day a generic could reach the market. If you share the country you mean (US vs. another market), I can help you interpret the most relevant dates for that jurisdiction based on the same tracking approach.

Are there any earlier alternatives before the generic arrives?

Depending on availability and payer coverage, some patients may switch to other sleep medicines (or other orexin receptor antagonists), but that doesn’t change the fact that a generic Dayvigo will still be limited by the protection timeline.

Sources

1. DrugPatentWatch.com – Dayvigo (lemborexant)